Giant cell arteritis: suspicion and follow-up in the community
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Suspected giant cell arteritis (after age 50)
- Visual symptom, even transient (blurring, amaurosis, diplopia): urgent corticosteroid therapy and specialist opinion the same day, without waiting for results.
Laboratory tests (the same day)
- CRP
- FBCif neededInflammatory anaemia and thrombocytosis are seen in half of cases [1]; not essential for the diagnosis.
- Fibrinogen (if CRP normal or nearly so)if neededAt diagnosis, CRP alone is necessary; other markers of inflammation can be explored if it is normal or almost normal, fibrinogen rather than ESR [1].
- Rheumatoid factorif neededIf there are joint manifestations, the PNDS recommends these tests to rule out rheumatoid arthritis with a rhizomelic onset, more frequent in older people [1].
- Anti-CCP antibodiesif neededIf there are joint manifestations, the PNDS recommends these tests to rule out rheumatoid arthritis with a rhizomelic onset, more frequent in older people [1].
- ANCA (anti-MPO and anti-PR3), to be discussed with the specialistif neededThe PNDS recommends this test for the differential diagnosis (ANCA-associated vasculitis, which can affect the temporal artery) [1].
- Fasting plasma glucose and HbA1c, before corticosteroid therapy (if risk factor for diabetes)if neededThe PNDS recommends screening for diabetes before corticosteroids in people at risk (overweight, personal or family history of diabetes, gestational diabetes) [1].
- IGRA test (before corticosteroid therapy, depending on tuberculosis risk)if needednon-French guidelineEULAR (2022) suggests considering screening for latent tuberculosis before corticosteroid therapy, especially beyond 15 mg/day of prednisolone for more than 4 weeks [3]; the BSR (2020) asks to discuss exposure to tuberculosis and to screen for it according to national protocols [4]. The PNDS asks to discuss antituberculosis prophylaxis in case of recent contact, old untreated tuberculosis or a positive tuberculin test, without requesting routine testing [1]. IGRA is not reimbursed in France for this indication [5].
Also consider
Do not order
Treated giant cell arteritis: laboratory monitoring
1 to 2 weeks after starting corticosteroids
- Serum potassium
At 1 month
- Venous plasma glucose, taken in late morning
Every month
- CRP
- Fibrinogen
- FBC (at each follow-up visit)if needednon-French guidelineThe BSR (2020) asks for at least an FBC with ESR or CRP at every follow-up visit, as platelets may be raised in giant cell arteritis [4]; the American Family Physician review (2022) also cites the FBC during follow-up [7]. In the PNDS, the FBC is part of the monitoring of tocilizumab and methotrexate [1].
Every 3 months (fasting)
- HbA1c
- Lipid profile
Do not order
- ESR for follow-up: the PNDS recommends fibrinogen as a slow marker [1].
Sources (8)
- Groupe d'étude français des artérites des gros vaisseaux (GEFA), filière FAI²R. Protocole national de diagnostic et de soins (PNDS) : artérite à cellules géantes (Horton). Haute Autorité de santé, janvier 2024.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1577 (HbA1c) et sous-chapitre 7-03 auto-immunité (acte 1462, ANCA) ; absence d'acte actif pour la vitesse de sédimentation.
- Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-753.
- Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1-e23.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 4103 (test IGRA), conditions de prise en charge.
- Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866-71.
- Raleigh MF, Stoddard J, Darrow HJ. Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review. Am Fam Physician. 2022;106(4):420-426.
- Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken). 2021;73(8):1071-1087.